Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/04/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/04/2020.
Displaying: 796 trials in your specialties ()
View trials across your selected specialties

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Carcinoma, Transitional Cell
View Full Trial
INTERVENTION

Drug: nanoparticle albumin-bound paclitaxel, S-1, Drug: Gemcitabine, cisplatin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Chinese PLA General Hospital, Beijing, China

Brief Summary

Gemcitabine plus cisplatin have been the most studied and used anticancer agents in patients with local advanced and/or metastatic transitional cell carcinoma of urothelial tract even if clinical benefits and survival remains limited. The purpose of this study is to test in a randomized trial enrolling patients for comparing the efficacy and safety of nab-paclitaxel plus S-1 with Gemcitabine plus cisplatin, in order to determine the most promising agents as the first line treatment of advanced and/or metastatic transitional cell carcinoma of urothelial tract.

TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Squamous Cell Lung Carcinoma
View Full Trial
INTERVENTION

Drug: TAS-102

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

UF Health Cancer Center, Gainesville, Florida, United States

Brief Summary

This is a non-randomized, open label, sequentially enrolling phase II study with a Simon two-step enrollment design to evaluate the activity of TAS-102 in previously treated unresectable or metastatic squamous non-small cell cancer after progression through or intolerance to prior systemic therapy. The trial therapy of TAS-102 is to be administered orally at 35 mg/m2 each dose twice daily. The primary objective of the trial is to determine the progression-free survival, in months, of subjects receiving TAS 102 for the treatment of unresectable or metastatic recurrent squamous non-small cell lung cancers.

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Solid Tumor
View Full Trial
INTERVENTION

Drug: Epacadostat, Drug: Pembrolizumab, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil, Drug: Gemcitabine, Drug: nab-Paclitaxel, Drug: Carboplatin, Drug: Paclitaxel, Drug: Pemetrexed, Drug: Cyclophosphamide, Drug: Carboplatin, Drug: Cisplatin, Drug: 5-Fluorouracil, Drug: Investigator's choice of platinum agent

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic Arizona, Phoenix, Arizona, United States

Brief Summary

This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as Treatment Groups A through G below (see Study Drug and Background Therapies, Dose, and Mode of Administration). Phase 1 consisted of a 3 + 3 + 3 design intended to determine the MTD or PAD of epacadostat when given in combination with pembrolizumab and chemotherapy; efficacy was also explored. Phase 2 was designed to enroll efficacy expansion cohorts to further evaluate the safety, tolerability, and efficacy of epacadostat at the MTD or PAD (as selected in Phase 1) when given in combination with pembrolizumab and chemotherapy. Each efficacy expansion cohort was to enroll participants with 1 specific type of advanced or metastatic solid tumor. Additional cohorts (ie, the mandatory biopsy cohorts) were designed to evaluate changes in the tumor microenvironment in participants with any advanced or metastatic solid tumor who had progressed on previous therapy with a PD-1 or a PD-L1 inhibitor. No participants were enrolled in any Phase 2 efficacy expansion cohort, or in any Phase 2 mandatory biopsy cohort receiving Treatment A, B, F, or G. Phase 2 mandatory biopsy cohort participants received Treatments C, D, or E (ie, were included in Treatment Groups C, D, or E). Participants were assigned to a treatment group based on the chemotherapy regimen most appropriate for their tumor type.

Study of NAC of GA Therapy for Patients With BRPC

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Ductal Adenocarcinoma
View Full Trial
INTERVENTION

Drug: Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hirosaki University, Hirosaki, Aomori, Japan

Brief Summary

Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer. Therefore, it was decided to consider the balance of safety and efficacy on survival time as a preoperative chemotherapy, the investigators use the NAC-GA regimen includes only two cycles (three times weekly and one week rest) of GA regimen.

Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Adenocarcinoma
View Full Trial
INTERVENTION

Drug: Gemcitabine, Drug: Nab-paclitaxel, Drug: Durvalumab, Drug: Tremelimumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Brief Summary

The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Neoplasms, Carcinoma, Non-Small-Cell Lung
View Full Trial
INTERVENTION

Drug: Epacadostat 25 mg, Drug: Epacadostat 100 mg, Drug: Epacadostat 300 mg, Biological: pembrolizumab 200 mg, Drug: Cisplatin 75 mg/m^2, Drug: Carboplatin Area Under the Curve (AUC)5, Drug: Pemetrexed 500 mg/m^2, Drug: Paclitaxel 200 mg/m^2, Drug: Carboplatin AUC6

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

This is an open-label, non-randomized, Phase I study of epacadostat (INCB024360) alone and in combination with pembrolizumab with chemotherapy and pembrolizumab without chemotherapy in participants with advanced solid tumors. The primary objective of the trial is to evaluate the safety and tolerability of epacadostat administered alone and in combination with pembrolizumab with and without chemotherapy.

A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Pancreatic Cancer
View Full Trial
INTERVENTION

Drug: FOLFIRINOX or gemcitabine/abraxane, Radiation: SBRT

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Colorado, Aurora, Colorado, United States

Brief Summary

This is a dose escalation trial to evaluate the safety of stereotactic body radiotherapy (SBRT) delivered in 3 fractions for patients with locally advanced pancreatic cancer (LAPC) who have received induction chemotherapy (FOLFIRINOX or gemcitabine and nab-paclitaxel).

Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Adenocarcinoma Pancreas
View Full Trial
INTERVENTION

Drug: Nab-paclitaxel, Drug: Gemcitabine, Other: Best Supportive Care

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Universitätsklinikum Mannheim II. Medizinische Klinik, Mannheim, Germany

Brief Summary

The hypothesis of the proposed study is that individualized assessment directed treatment algorithms identifies elderly patients, who benefit from combined nab-paclitaxel/gemcitabine therapy. The project uses a CGA, which includes various tests and scoring systems, to stratify patients as "GO-GO", "SLOW-GO" or "FRAIL" patients. Depending on test results patients receive chemotherapy (GO-GO group: nab-paclitaxel/gemcitabine; SLOW-GO group: gemcitabine monotherapy) or best supportive care (FRAIL group). After the first cycle of chemotherapy (4 weeks) a subsequent CGA and a safety assessment will be performed to assign patients to their definite treatment arm. The primary objective is that CGA-stratified patients do not decline in their CGA performance in response to chemotherapy measured as a loss of five points or less in the Barthel`s ADL (ADL1 vs. ADL2 during core CGA assessment).

First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Metastatic Pancreatic Adenocarcinoma
View Full Trial
INTERVENTION

Drug: GEMBRAX, Drug: FOLFIRINOX

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Institut regional du Cancer - Val d Aurelle, Montpellier, France

Brief Summary

Based on conventional chemotherapy approach, data have indicated that the Folfirinox regimen is more effective and tolerate than the treatment by Gemcitabine alone in patients with metastatic pancreatic adenocarcinoma. A recent study combining gemcitabine and nab paclitaxel improve the objective response rate. Primary objective of this study is to identify the maximun tolerated dose and the recommended phase II dose of first line treatment combining gemcitabine plus nab-paclitaxel followed by folfirinox in metastatic pancreatic adenocarcinoma.

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Non-small Cell Lung Carcinoma
View Full Trial
INTERVENTION

Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Carboplatin, Biological: Bevacizumab, Drug: Pemetrexed, Biological: Ipilimumab, Drug: Erlotinib, Drug: Gefitinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung cancer (NSCLC).